Hospital Top Page

 

TOP >>Main Part 2012 >>2-2 >>Nephrology

Top | Next Page | Preceding Page

Profile of Nagoya University Hospital 2012

Part2 Information on Departments, Facilities, etc.

Nephrology
Director MARUYAMA, Shoichi (Extraordinary Professor)   10E
We provide medical care for all diseases related to the kidney with the latest therapies
We treat various renal diseases after carefully examining information based on accurate evidence and obtaining full understanding from the patient and family.

Medical Care System

Our department consists of about 15 full-time and part-time doctors. Medical care is provided mainly by professors who are nephrology specialists. We hold a conference twice a week and determine the course of treatment.

Target Disease

All diseases related to the kidney including renal disease such as nephritis, nephrotic syndrome, renal failure, hypertensive renal disorder, diabetic nephropathy, collagen disorder, systemic vasculitis syndrome and management after renal transplantation and electrolyte and acid-base balance disorder.

Strong Fields

We are actively involved in renal pathological diagnosis, renal replacement therapy, and new immunosuppressive therapies using ciclosporin, tacrolimus, etc. and alpha-glucosidase replacement therapy for diseases such as refractory nephrotic syndrome, collagen disorder, and hereditary diseases.

Clinical Results

Annual number of inpatients: 323; number of pathological diagnosis by renal biopsy: 608 (our hospital: 47, affiliated facilities: 561); number of patients in whom dialysis was newly introduced: 35 (hemodialysis: 24, peritoneal dialysis 11); other patients (plasma exchange therapy and selective blood cell component adsorption therapy; total number of patients: 287).

Specialized Outpatient Clinic

Outpatient clinic for peritoneal dialysis and outpatient clinic for chronic kidney disease (CKD).

Advanced Medicine and Research

We are involved in laparoscopic renal biopsy (in cooperation with Urology) for high-risk patients, research on renal regeneration using adipose stem cells, development of urinary biomarkers for acute renal disorders, development of antihypertensive drugs using RAS inhibitory molecules, and elucidation of the mechanism of peritoneal fibrosis.

Top of Page